Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2002-10-26
2010-06-08
Juedes, Amy E (Department: 1644)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S278100
Reexamination Certificate
active
07731945
ABSTRACT:
A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α1.
REFERENCES:
patent: 4116951 (1978-09-01), Wang
patent: 4353821 (1982-10-01), Birr et al.
patent: 4390623 (1983-06-01), Frabricius et al.
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4454355 (1984-06-01), Schubert et al.
patent: 4466918 (1984-08-01), Birr et al.
patent: 4470926 (1984-09-01), Birr et al.
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4612365 (1986-09-01), Birr et al.
patent: 4910296 (1990-03-01), Birr et al.
patent: 4925678 (1990-05-01), Ranney
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5100664 (1992-03-01), Doyle et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5503841 (1996-04-01), Doyle et al.
patent: 5632983 (1997-05-01), Hadden
patent: 5643565 (1997-07-01), Doyle et al.
patent: 5698194 (1997-12-01), Hadden
patent: 5800810 (1998-09-01), Doyle et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 6977072 (2005-12-01), Hadden
patent: 2002/0034494 (2002-03-01), Vicari et al.
patent: 0 974 357 (1998-07-01), None
Syrjanen, 2005, J. clinical Virology, vol. 32S: S59-66.
Mastino et al., 1992, Int. J. Cancer vol. 50: 493-99.
The Merck Manual of Diagnosis and Therapy, 1995, p. 1-3.
Siveke et al., 2004, Expert Opinion Biol. Ther. vol. 4:1719-1727.
Hadden et al., 1994, Arch Otolaryngol Head Neck Surg. vol. 120: 395-403.
Hadden, 1995, Int. J. Immunpharmac, vol. 17: 821-828.
Burgers et al., 2005, Best Practice and Research Clinical Obstetrics and Gynaecology, vol. 19: 277-291.
Janeway and Travers, 1997, Immunobiology, p. 13:23-24.
Rasi, G., et al. Combined treatment with thymosin-alpha after dacarbazine in advanced melanoma. Melanom Research, vol. 10, No. 2, Apr. 2000, pp. 189-192.
Silecchia G., et al. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunology and Immunotherapy, Berlin, DE, vol. 48, 1999, pp. 172-178.
Hadden, J. et al., “A trial of IRX-2 in patents with squamous cell carcinomas of the head and neck,”International Immunopharmacology, 3:1073-1081 (2003).
Albert et al, “letter to nature”, Nature, vol. 392, pp. 86-89, 1998.
Banchereau, et al. “Immunology of Dendritic Cells,” Annu. Rev. Immunol. 2000, 18:767-811.
Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. “Combination immunotherapy of squamous cell head and neck cancer: A phase II trial”, Arch Otolaryngol Head Neck Surg 126:345-351, 2000.
Bellone et al. “Cancer immunotherapy: synthetic and natural peptides in the balance”, Immunology Today, vol. 20, No. 10, p. 457-462, 1999.
Berd D, Mastrangelo MJ. “Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T suppressor function without depletion of the CD8+subset”, Cancer Research 47:3317-3321, 1987.
Berd D. “Low doses of chemotherapy to inhibit suppressor T cells”, Progress in Clin Biol Res 288:449-458, 1989.
Borysiewickz LK, Fiander A, Nimako M., Man, S., Wilkinson, GW., Westmoreland, D., Evans, AS., Adams, M., Stacey, SN., Boursnell, ME., Rutherford, E., Hickling, JK., Inglis, SC. “A recombinant vaccine virus encoding human papilomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer”, Lancet 347: 1524-1527, 1996.
Burke and Olson, Methods in Enzymology, vol. 194, “Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors”, eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270, 1991.
Capecchi, MR. “Altering the genome by homologous recombination”, Science 244:1288-1292, 1989.
Cortesina G, DeStefani A, Galcazzi E. “Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low dose but not a high dose of recombinant interlukin 2 injected perilymphactically”, Br J Cancer 69:572-577, 1994.
Cortesina G, DeStefani A, Giovarelli M, et al. “Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of intereukin-2 injected perilymphatically”, Cancer 62:2482-2485, 1988.
Cregg JM, Vedvick TS, Raschke WC. “Recent Advances in the Expression of Foreign Genes inPichia pastoris”, Bio/Tehnoloqy 11:905-910, 1993.
Dallal, RM., Lotze, MT. The dendritic cell and human cancer vaccines, Current Opinion in Immunology 2000, vol. 12, pp. 583-588.
Davies, NP., Rosewell, IR., Brüggemann, M. “Targeted alterations in yeast artificial chromosomes for interspecies gene transfer”, Nucleic Acids Research, vol. 20, No. 11, pp. 2693-2698, 1992.
Deans JP., Boyd AW., Pilarski LM., Transitions from High to Low Molecular Weight Isoforms of CD45 (T200) Involve Rapid Activation of Alternate mRNA Splicing and Slow Turnover of Surface CD45R, The Journal of Immunology, 143:1233-1238, No. 4, Aug. 15, 1989.
Deans JP., Shaw J., Pearse MJ., Pilarski LM., CD45R as a Primary Signal Transducer Stimulating IL-2 and IL-2R mRNA Synthesis by CD3-4-8-Thymocytes, The Journal of Immunology, 143:2425-2430, No. 8, Oct. 15, 1989.
Dickinson, P., Kimber, WL., Kilanowski, FM., Stevenson, B.J., Porteous, DJ., Dorin, JR. “High frequency gene targeting using insertional vector”, Human Molecular Genetics, vol. 2, No. 8, pp. 1299-1302, 1993.
Duff and Lincoln. “Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells”, Research Advances in Alzheimer's Disease and Related Disorders, 1995.
Gilboa E, Eglitis MA, Kantoff PW, Anderson WF. “Transfer and expression of cloned genes using retroviral vectors”, BioTechniques 4(6):504-512, 1986.
Gillis S. et al., J. Immunology 120:2027-2032, 1978.
Hadden J. et al., Immunopharmacology, JAMA, 268:20:2964-2969, 1992.
Hadden JW. “T-Cell Adjuvants”, Int. J. Immunopharmac., vol. 16, No. 9, pp. 703-710, 1994.
Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. “Interleukins and contrasuppression induce immune regression of head and neck cancer”, Arch otolaryngol Head Neck Surg. 120:395-403, 1994.
Hadden JW, Shah AR, Sosa M, Hadden EM. “Immunotherapy with natural interleukins and/or Thymosin α1potently augments T lymphocyte responses of hydrocortisone-treated aged mices”, Int'l J Immunopharmacol 17:821-828, 1995.
Hadden JW. “The immunology and immunotherapy of breast cancer: An update”, Int'l J Immunopharmacol 21:79-101, 1999.
Haddden JW. “The immunopharmacology of head and neck cancer: An update”, Int'l J Immunopharmacol 11/12:629-644, 1997.
Hadden JW. “The treatment of zinc deficiency is an immunotherapy”, Int'l J Immunopharmacol 17:696-701, 1995.
Hank JA., Albertini, MR., Sondel, PM. “Monoclonal antibodies, cytokines and fu
Immuno-Rx, Inc.
Juedes Amy E
Kohn & Associates PLLC
LandOfFree
Immunotherapy for reversing immune suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy for reversing immune suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy for reversing immune suppression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199143